Los Angeles, California (PRWEB) February 01, 2014
The buyer power score for anticoagulants is 3.5 out of 5. The higher the score, the better negotiating conditions for buyers. The score for anticoagulants reflects the low market risk and high availability of options for buyers. Anticoagulants are most commonly used as a medication for elderly adults to resolve symptoms of strokes and heart attacks or as a prophylaxis to prevent these age-related disorders. “Because the population of adults aged 65 and older is expected to increase over the next three years, demand for anticoagulants anticipated to rise,” says IBISWorld procurement analyst Keiko Cadby. Additionally, the number of individuals with health insurance is expected to increase in the coming years due to healthcare reform legislation, further driving up demand. These increases in demand, along with the emergence of new and expensive anticoagulant drugs, are expected to cause the average price of anticoagulant products to increase.
The market share concentration for anticoagulants is low, even though there is a trend of consolidation among companies. “A low market share concentration means buyers have multiple options for where to obtain anticoagulants, increasing buyer power,” says Cadby. Anticoagulant manufacturers, wholesalers and distributors are highly competitive and may be willing to discount their products if a buyer threatens to make the switch to a different supplier. Meanwhile, supplier consolidation helps reduce input costs (e.g. research and development costs), which are high for pharmaceutical manufacturers, and these cost savings may be passed down to the buyer in the form of cheaper prices. Major suppliers include Boehringer Ingelheim, Bristol-Myers Squibb Company, Roche and Sanofi.
Buyers can increase their negotiating power by opening up to more anticoagulant options, such as alternative brands or generics. Generic brand anticoagulants are drug products that use the same active ingredients as their brand name counterparts, but lack some of the research and development efforts that brand name manufacturers have invested while the drug was patented. Switching costs are affected by the loss of familiarity or quality when converting to a new brand or to a generic. Thus, buyers should make agreements that allow them to switch to other brands or arrange discounts when generics arrive on the market.
For more information, visit IBISWorld’s anticoagulants procurement category market research report page.
Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld
Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189
IBISWorld Procurement Report Key Topics
This report is intended to assist buyers of anticoagulants. Anticoagulants are agents used to prevent blood from clotting or prevent existing clots from getting larger in the heart, veins or arteries. They can be used as a medication, a coating on medical equipment or as a rodenticide. A number of anticoagulants are available, including warfarin, dalteparin, enoxaparin, dabigatran and rivaroxaban, each of which are sold under various brand names. Suppliers of anticoagulants include manufacturers, wholesalers, and pharmacies.
Recent Price Trend
Product Life Cycle
Total Cost of Ownership
Supply Chain & Vendors
Supply Chain Dynamics
Supply Chain Risk
Market Share Concentration
Vendor Financial Benchmarks
Buying Lead Time
Key RFP Elements
Buyer Power Factors
About IBISWorld Inc.
IBISWorld is one of the world's leading publishers of business intelligence, specializing in Industry research and Procurement research. Since 1971, IBISWorld has provided thoroughly researched, accurate and current business information. With an extensive online portfolio, valued for its depth and scope, IBISWorld’s procurement research reports equip clients with the insight necessary to make better purchasing decisions, faster. Headquartered in Los Angeles, IBISWorld Procurement serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.